<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957616</url>
  </required_header>
  <id_info>
    <org_study_id>IPNSAE</org_study_id>
    <nct_id>NCT03957616</nct_id>
  </id_info>
  <brief_title>Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis</brief_title>
  <acronym>IPNSAE</acronym>
  <official_title>Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to provide an estimate of the incidence of paraneoplastic neurological
      syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study
      will describe the incidence of antibody subtypes and regional variations.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018.</measure>
    <time_frame>3 years</time_frame>
    <description>Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Location (city) of diagnosis</measure>
    <time_frame>1 hour</time_frame>
    <description>Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>French general population of each counties</measure>
    <time_frame>3 years</time_frame>
    <description>Person years for each region</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Paraneoplastic Neurological Syndrome</condition>
  <condition>Autoimmune Encephalitis</condition>
  <arm_group>
    <arm_group_label>Paraneoplastic neurological syndromes patients</arm_group_label>
    <description>Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with a paraneoplastic neurological syndrome or autoimmune encephalitis
        in France and referred to the national center in Lyon between 2016 and 2018.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune
        Encephalitis (AE) made by the referring physician to the national center for PNS and AE in
        Lyon between 2016 and 2018

        Exclusion Criteria:

          -  Data on location of diagnosis missing

          -  Patients diagnosed out of the mainland French territory

          -  Patients for whom insufficient data was available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Honnorat</last_name>
    <role>Principal Investigator</role>
    <affiliation>center for paraneoplastic neurological syndromes and autoimmune encephalitis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Géraldine Picard</last_name>
    <phone>4 72 35 58 42</phone>
    <phone_ext>33</phone_ext>
    <email>geraldine.picard@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme Honnorat</last_name>
    <phone>4 72 35 78 06</phone>
    <phone_ext>33</phone_ext>
    <email>jerome.honnorat@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

